CureVac (CDMO Services)

Tubingen, DE
Hybrid — also manufactures internal programs
mRNA
No confirmed program data — ClinicalTrials.gov verification pending · Last scored 2026-09-07
75.3
Signal Score
○ FDA Inspections ✓ Clinical Trials (4) ○ SEC Filings ○ Press ✓ EMA GMP (7) ○ MHRA GMP

Quick Facts: CureVac (CDMO Services)

Signal Score
75.3/100 (as of 2026-09-07)
Quality Compliance
100.0/100
Headquarters
Tubingen, DE
Modalities
mRNA
Active Programs
Data pending
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About CureVac (CDMO Services)

mRNA pioneer with CDMO capabilities.

Signal Score & Pillar Breakdown

Scores are being republished. Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance 100.0
FDA InspectionsNo US records on file
EMA GMP Certificates7 on record
Operations 52.5
Programs — no verified data
Sponsors— no verified data
ModalitiesmRNA
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
NCT07073183 Safety and Tolerability of CVHNLC Plus Pembrolizumab in... PHASE1 Withdrawn
NCT03291002 Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC PHASE1 Unknown
NCT01915524 Trial of RNActive®-Derived Cancer Vaccine and Local Radiation... PHASE1 Terminated
NCT00923312 Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV... PHASE1/PHASE2 Completed
Source: ClinicalTrials.gov · Retrieved Oct 07, 2026
Financial Stability 83.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity 53.0
Profile-based capacity assessment

CureVac (CDMO Services) EMA GMP Compliance 7 certificates

2025-11
2025-11
2025-11
2024-12
2023-09
2023-09
2023-05
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
DE_BW_01_GMP_2026_0102 CureVac Manufacturing GmbH Germany 2025-11-13 COMPLIANT
DE_BW_01_GMP_2026_0103 CureVac Manufacturing GmbH Germany 2025-11-13 COMPLIANT
DE_BW_01_GMP_2026_0101 CureVac Manufacturing GmbH Germany 2025-11-13 COMPLIANT
DE_BW_01_GMP_2025_0094 CureVac Manufacturing GmbH Germany 2024-12-17 COMPLIANT
DE_BW_01_GMP_2024_0013 CureVac Manufacturing GmbH Germany 2023-09-28 COMPLIANT
DE_BW_01_GMP_2024_0012 CureVac Manufacturing GmbH Germany 2023-09-28 COMPLIANT
DE_BW_01_GMP_2023_0203 CureVac RNA Printer GmbH Germany 2023-05-23 COMPLIANT
Source: EMA EudraGMDP · Retrieved Oct 07, 2026

Frequently Asked Questions About CureVac (CDMO Services)

Does CureVac (CDMO Services) hold EMA or MHRA GMP certificates?
CDMO Signal tracks 7 EMA GMP certificates for CureVac (CDMO Services).
How many clinical programs is CureVac (CDMO Services) linked to?
CureVac (CDMO Services) is associated with 4 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is CureVac (CDMO Services)'s CDMO Signal Score?
CureVac (CDMO Services) has a Signal Score of 75/100, based on quality, operations, financial stability, and capacity data.
Evaluating CureVac (CDMO Services) for a manufacturing program?
Use the free AI matchmaker to compare CureVac (CDMO Services) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
mRNA CDMOs →

Similar CDMOs

BioNTech (Mfg Services)
Mainz, DE · Marburg, DE
Signal Score: 84.9
mRNA
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
Signal Score: 81.8
mRNA, Biologics, Cell Therapy
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
Signal Score: 81.6
Recombinant Protein, Plasmid DNA, mRNA
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 81.1
mRNA, Oligonucleotide, Biologics
Ethris
Planegg, DE
Signal Score: 56.5
mRNA